Inhibrx Biosciences logo
Inhibrx Biosciences
INBX | NASDAQ
Chart Builder DCF Calculator
$77.66
-$5.64 (-6.77%)
At close: Nov 16, 2026, 4:00 PM ET
$77.55
-$0.11 (-0.14%)
After-hours: Nov 16, 2026, 7:32 PM ET

Inhibrx Biosciences Company Profile

Company profile explained

Company Profile

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Key Executives

Name Position
Mark Paul Lappe Founder, Chief Executive Officer & Chairman
Kelly Devine Deck Executive Vice President, Chief Financial Officer & Treasurer
Ashraf Amanullah Executive Vice President & Chief Technical Operations Officer
Bonne Adams Vice President of Operations
Carlos Bais EVice President & Chief Scientific Officer
David Matly President
Josep Garcia Executive Vice President & Chief Clinical Development Officer
Kate Burke Vice President of Accounting
Leah Pollema Vice President, General Counsel & Corporate Secretary

Latest SEC Filings

Date Type Title
Oct 28, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 14, 2026 4 Filing
Sep 28, 2026 4 Filing
Sep 28, 2026 8-K Current Report
Sep 23, 2026 4 Filing
Sep 18, 2026 4/A [Amend] Filing
Sep 18, 2026 4/A [Amend] Filing
Sep 18, 2026 4/A [Amend] Filing
Sep 18, 2026 4/A [Amend] Filing
Sep 17, 2026 4 Filing
View All SEC Filings ➞
Inhibrx Biosciences
Inhibrx Biosciences logo
Country United States
IPO Date May 29, 2024
Industry Biotechnology
Sector Healthcare
Employees 110
CEO Mark Lappe

Contact Details

11025 North Torrey Pines Road La Jolla, California 92037 United States

Stock Details

Ticker Symbol INBX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0002007919
CUSIP Number 45720N103
ISIN Number US45720N1037
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.